Deltex Medical Group PLC Grant of Options (1455A)
22 March 2017 - 6:15PM
UK Regulatory
TIDMDEMG
RNS Number : 1455A
Deltex Medical Group PLC
22 March 2017
Dissemination of a Regulatory Announcement that contains inside
information according to REGULATION (EU) No 596/2014 (MAR).
22 March 2017
Deltex Medical Group plc
("Deltex Medical" or "the Company")
Grant of options
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), today announces that the
Board has approved the issue of share options to Ewan Phillips,
Chief Executive and Jonathan Shaw, Group Finance Director.
Employee Share Option Scheme
The Board has approved the issue of 658,743 and 404,762 share
options to Ewan Phillips and Jonathan Shaw, respectively under the
Company's 2003 Share Option Scheme ("EMI"). The exercise price is 1
pence per share option.
The awards were made in return for the directors agreeing to
waive gross salary and benefits of GBP17,292 and GBP10,625
respectively.
Confirmation of Directors interest in share options
Following the grant of EMI options above, the options held by
the Executive Directors are shown below:
Executive 2001 Executive 2011 Executive EMI Share
Director Share Scheme Share Scheme Scheme Total
Number Number Number Number
--------------- --------------- --------------- ---------- ----------
Ewan Phillips 1,400,000 2,750,000 2,995,954 7,145,954
Jonathan
Shaw - - 404,762 404,762
--------------- --------------- --------------- ---------- ----------
Additional interests
Following the Subscription announced this morning, Mr Phillips
will have a beneficial interest in 2,921,051 ordinary shares in the
Company representing 0.98 per cent of the issued ordinary share
capital of the Company. Mr Shaw will have a beneficial interest in
262,931 ordinary shares in the Company representing 0.09 per cent
of the issued ordinary share capital of the Company.
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them.
The following notifications are made in accordance with Article
19 of the EU Market Abuse Regulation
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Ewan Phillips
--- --------------------------- -----------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Executive Director
--- --------------------------- -----------------------------------
b) Initial notification Initial
/Amendment
--- --------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------------------
a) Name Deltex Medical Group plc
--- --------------------------- -----------------------------------
b) LEI N/A
--- --------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------------------
a) Description of Unconditional awards over
the financial instrument, Ordinary shares of 1p each
type of instrument in Deltex Medical Group
plc
Identification
code Identification code (ISIN)
for Deltex Medical Group
plc ordinary shares: GB0059337583
--- --------------------------- -----------------------------------
b) Nature of the transaction Share subscription
--- --------------------------- -----------------------------------
c) Price(s) and volume(s) Unconditional award over
658,743 shares under the
Deltex Medical 2003 Share
Option Scheme
--- --------------------------- -----------------------------------
d) Aggregated information
- Aggregated volume
- Price
--- --------------------------- -----------------------------------
e) Date of the transaction 22 March 2017
--- --------------------------- -----------------------------------
f) Place of the transaction Grant of share awards occurred
outside of a trading venue.
--- --------------------------- -----------------------------------
1 Details of the person discharging managerial
responsibilities / person closely associated
--- ----------------------------------------------------------------
a) Name Jonathan Shaw
--- --------------------------- -----------------------------------
2 Reason for the notification
--- ----------------------------------------------------------------
a) Position/status Executive Director
--- --------------------------- -----------------------------------
b) Initial notification Initial
/Amendment
--- --------------------------- -----------------------------------
3 Details of the issuer, emission allowance
market participant, auction platform, auctioneer
or auction monitor
--- ----------------------------------------------------------------
a) Name Deltex Medical Group plc
--- --------------------------- -----------------------------------
b) LEI N/A
--- --------------------------- -----------------------------------
4 Details of the transaction(s): section to
be repeated for (i) each type of instrument;
(ii) each type of transaction; (iii) each
date; and (iv) each place where transactions
have been conducted
--- ----------------------------------------------------------------
a) Description of Unconditional awards over
the financial instrument, Ordinary shares of 1p each
type of instrument in Deltex Medical Group
plc
Identification
code Identification code (ISIN)
for Deltex Medical Group
plc ordinary shares: GB0059337583
--- --------------------------- -----------------------------------
b) Nature of the transaction Share subscription
--- --------------------------- -----------------------------------
c) Price(s) and volume(s) Unconditional award over
404,762 shares under the
Deltex Medical 2003 Share
Option Scheme
--- --------------------------- -----------------------------------
d) Aggregated information
- Aggregated volume
- Price
--- --------------------------- -----------------------------------
e) Date of the transaction 22 March 2017
--- --------------------------- -----------------------------------
f) Place of the transaction Grant of share awards occurred
outside of a trading venue.
--- --------------------------- -----------------------------------
For further information, please contact:-
Deltex Medical Group 01243 774 837
plc investorinfo@deltexmedical.com
Nigel Keen, Chairman
Ewan Phillips, Chief
Executive
Jonathan Shaw, Group
Finance Director
Nominated Adviser &
Broker
Arden Partners plc 020 7614 5900
Chris Hardie
Financial Public Relations
IFC Advisory Ltd 0203 053 8671
Tim Metcalfe
Graham Herring
Heather Armstrong
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies. Deltex Medical's ODM is the only technology to
measure continuously blood flow in the central circulation in real
time. Minimally invasive, easy to set up and quick to focus, the
technology generates a low-frequency ultrasound signal, which is
highly sensitive to changes in flow and measures them immediately.
Deltex has been the only company in the enhanced haemodynamic space
to build a robust and credible evidence base proving the clinical
and economic benefits of its core technology, ODM. Randomised,
controlled trials using Doppler have demonstrated that early fluid
management intervention will reduce post-operative complications,
reduce intensive care admissions, and reduce the length of hospital
stay.
Company goal
ODM is increasingly recognised as a standard of care for
patients undergoing major surgery and in critical care. The broader
clinical area of haemodynamic management of which ODM is a core
constituent is also now becoming widely accepted as an important
major new medical modality. Consequently, the Company's focus is on
maximising value from the opportunities presented as enhanced
haemodynamic management is adopted into routine clinical practice
around the world.
The Company is currently in the implementation phase of
achieving this goal in a number of territories worldwide, operating
directly in the UK, USA, Spain and Canada and through distribution
arrangements in a further 30 countries.
There are over 3,200 monitors installed in hospitals around the
world and around 700,000 patients have been treated to date using
Deltex Medical's single patient disposable probes.
This information is provided by RNS
The company news service from the London Stock Exchange
END
DSHLFFELVRILFID
(END) Dow Jones Newswires
March 22, 2017 03:15 ET (07:15 GMT)
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From May 2024 to Jun 2024
Deltex Medical (LSE:DEMG)
Historical Stock Chart
From Jun 2023 to Jun 2024